Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: February 10, 2004
Last updated: February 8, 2013
Last verified: February 2005
This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.

Condition Intervention Phase
Drug: romidepsin
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study Of Depsipeptide, A Histone Deacetylase Inhibitor, In Relapsed Or Refractory Mantle Cell Or Diffuse Large Cell Non-Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Enrollment: 35
Study Start Date: January 2004
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: romidepsin

Detailed Description:


I. Determine the response rate (complete and partial) in patients with relapsed or refractory Burkitt's, mantle cell or diffuse large cell non-Hodgkin's lymphoma treated with FR901228 (depsipeptide).

II. Determine the safety and feasibility of this drug, in terms of incidence and maximum grade of toxicity and courses delayed or doses reduced, in these patients.

III. Determine the 2-year progression-free survival and overall survival of patients treated with this drug.

IV. Correlate tumor expression of BCL-2, BCL-6, BAX, and RAS with response in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months until disease progression and then every 6 months until 5 years from study registration.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma of 1 of the following cellular types:

    • Diffuse large cell
    • Mantle cell
    • Burkitt's
  • Relapsed or refractory disease

    • No more than 2 prior regimen for patients with refractory disease
    • Any number of prior therapies (including peripheral blood stem cell or bone marrow transplantation) allowed for patients with relapsed disease provided there was an objective response to the most recent therapy
  • Measurable disease

    • At least 1 lesion ≥ 1.5 cm in diameter
  • No transformed lymphoma
  • No CNS lymphoma
  • Ineligible for, refused, or relapsed after stem cell transplantation



  • 18 and over

Performance status

  • ECOG 0-2


  • Absolute neutrophil count ≥ 1,000/mm^3 (500/mm^3 in patients with extensive bone marrow involvement [> 50%] or hypersplenism with palpable splenomegaly)
  • Platelet count ≥ 75,000/mm^3 (50,000/mm^3 in patients with extensive bone marrow involvement or hypersplenism with palpable splenomegaly)


  • Bilirubin ≤ upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2 times ULN
  • AST ≤ 2 times ULN


  • Creatinine ≤ ULN


  • QTc < 500 msec by ECG
  • Cardiac function ≥ 50% by MUGA
  • No prior serious ventricular arrhythmia
  • No New York Heart Association class III or IV congestive heart failure
  • No significant cardiac hypertrophy by ECG
  • No other significant cardiac disease


  • No chronic obstructive pulmonary disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No active infection
  • No diabetes
  • No other uncontrolled serious medical condition



  • Prior cumulative doxorubicin dose < 450 mg/m^2
  • Prior cumulative mitoxantrone dose < 112 mg/m^2
  • Prior doxorubicin equivalent dose < 450 mg/m^2 (for patients who have previously received both doxorubicin and mitoxantrone)


  • Recovered from all prior therapy
  • No prior histone deacetylase inhibitor therapy
  • No concurrent medication associated with QTc prolongation, such as dolasetron
  • Concurrent hydrochlorothiazide, furosemide, or other diuretics allowed provided patient is on concurrent potassium chloride supplementation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00077194

United States, District of Columbia
Howard University Cancer Center at Howard University Hospital
Washington, District of Columbia, United States, 20060
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792-5256
Sponsors and Collaborators
National Cancer Institute (NCI)
Study Chair: Nancy L. Bartlett, MD Washington University Siteman Cancer Center
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00077194     History of Changes
Other Study ID Numbers: NCI-2012-02571
CDR0000349660 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: February 10, 2004
Last Updated: February 8, 2013

Keywords provided by National Cancer Institute (NCI):
recurrent adult diffuse large cell lymphoma
recurrent mantle cell lymphoma
recurrent adult Burkitt lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Histone Deacetylase Inhibitors
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017